Clinical Trials
3 trialsNCT00496431 2022-01-27
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Italfarmaco
Phase 1/2 Terminated
NCT00792831 2022-01-27
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Italfarmaco
Phase 2 Terminated
NCT00792467 2021-05-11
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Italfarmaco
Phase 1/2 Completed